Skip to search formSkip to main contentSkip to account menu

0.6 ML Fondaparinux sodium 12.5 MG/ML Prefilled Syringe [Arixtra]

Known as: FONDAPARINUX SODIUM 7.5 mg in 0.6 mL SUBCUTANEOUS INJECTION, SOLUTION [ARIXTRA], 0.6 ML Arixtra 12.5 MG/ML Prefilled Syringe, Arixtra 7.5 MG in 0.6 ML Prefilled Syringe 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2021
Review
2021
SummaryAbstractFondaparinux sodium (Arixtra®) is a synthetic, sulfated pentasaccharide, selective factor Xa inhibitor that is… 
2019
2019
Glycosaminoglycans (GAGs) are carbohydrate polyionic polymers that participate in a host of critically important biological… 
2015
2015
We validate the utility of ion mobility to measure protein conformational changes induced by the binding of glycosaminoglycan… 
2012
2012
SummaryAbstractFondaparinux sodium (Arixtra®; fondaparinux) is the first of a new class of synthetic pentasaccharide… 
2004
2004
Auteur(s) :, Roger Cariou* Departement therapeutique thrombose, Sanofi Synthelabo Recherche, 91385 Chilly Mazarin cedex, France… 
2004
2004
Background: The MATISSE trials showed that a single dose regimen of fondaparinux, a synthetic selective factor Xa inhibitor, was… 
2002
2002
  • P. Giangrande
  • The Medical letter on drugs and therapeutics
  • 2002
  • Corpus ID: 2714295
Fondaparinux is a promising new antithrombotic agent. This pentasaccharide selectively and specifically inhibits coagulation…